GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoviricides Inc (AMEX:NNVC) » Definitions » Cyclically Adjusted Price-to-FCF

Nanoviricides (Nanoviricides) Cyclically Adjusted Price-to-FCF : (As of Apr. 30, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Nanoviricides Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Nanoviricides Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Nanoviricides's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanoviricides Cyclically Adjusted Price-to-FCF Chart

Nanoviricides Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nanoviricides Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nanoviricides's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Nanoviricides's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanoviricides's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanoviricides's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Nanoviricides's Cyclically Adjusted Price-to-FCF falls into.



Nanoviricides Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Nanoviricides's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Nanoviricides's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.147/129.4194*129.4194
=-0.147

Current CPI (Dec. 2023) = 129.4194.

Nanoviricides Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -1.134 99.695 -1.472
201406 -0.952 100.560 -1.225
201409 -0.813 100.428 -1.048
201412 -2.000 99.070 -2.613
201503 -0.785 99.621 -1.020
201506 -0.820 100.684 -1.054
201509 -0.694 100.392 -0.895
201512 -0.432 99.792 -0.560
201603 -0.913 100.470 -1.176
201606 -0.495 101.688 -0.630
201609 -0.773 101.861 -0.982
201612 -0.897 101.863 -1.140
201703 -0.704 102.862 -0.886
201706 -0.335 103.349 -0.420
201709 -0.501 104.136 -0.623
201712 -0.463 104.011 -0.576
201803 -0.446 105.290 -0.548
201806 -1.025 106.317 -1.248
201809 -0.289 106.507 -0.351
201812 -0.628 105.998 -0.767
201903 -0.561 107.251 -0.677
201906 -0.438 108.070 -0.525
201909 -0.374 108.329 -0.447
201912 -0.292 108.420 -0.349
202003 -0.368 108.902 -0.437
202006 -0.207 108.767 -0.246
202009 -0.217 109.815 -0.256
202012 -0.218 109.897 -0.257
202103 -0.141 111.754 -0.163
202106 -0.201 114.631 -0.227
202109 -0.065 115.734 -0.073
202112 -0.199 117.630 -0.219
202203 -0.147 121.301 -0.157
202206 -0.127 125.017 -0.131
202209 -0.093 125.227 -0.096
202212 -0.125 125.222 -0.129
202303 -0.154 127.348 -0.157
202306 -0.129 128.729 -0.130
202309 -0.101 129.860 -0.101
202312 -0.147 129.419 -0.147

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Nanoviricides  (AMEX:NNVC) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Nanoviricides Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Nanoviricides's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanoviricides (Nanoviricides) Business Description

Industry
Traded in Other Exchanges
Address
1 Controls Drive, Shelton, CT, USA, 06484
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
Executives
Makarand Jawadakar director C.O NANOVIRICIDES, INC, 1 CONTROLS DRIVE, SHELTON CT 06484
Mark D. Day director C/O NANOVIRICIDES, INC., 1 CONTROLS DRIVE, SHELTON CT 06484
Milton Boniuk director C/O NANOVIRICIDES, INC., 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Anil Diwan director, 10 percent owner, officer: President 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Mukund S Kulkarni director C/O NANOVIRICIDES, INC., 135 WOOD ST, SUITE 205, WEST HAVEN CT 06516
Meeta Vyas officer: Chief Financial Officer 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Eugene Seymour director, 10 percent owner 666 THIRD AVENUE, NEW YORK NY 10017
Theracour Pharma, Inc. 10 percent owner 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516

Nanoviricides (Nanoviricides) Headlines

From GuruFocus